Trial reportJournal of pediatric hematology/oncology2012
Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group.
Trial report in Journal of pediatric hematology/oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Guideline
- The under reporting of recruitment strategies in research with children with life-threatening illnesses: A systematic review.Palliative medicine · 2017Pooled it
- Trial
- Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004.Haematologica · 2016Trial
- Bacterial Pathogen Profiles and Antibiotic Resistance in Pediatric Leukemia Patients: Insights for Optimizing Infection Management in Immunocompromised Children.Antibiotics (Basel, Switzerland) · 2024Article
- Levofloxacin prophylaxis for pediatric leukemia patients: monitoring of outcomes for sustained benefit and consequences.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- Fungal infections in pediatric patients with acute myeloid leukemia in a tertiary hospital.Frontiers in public health · 2023Article
- Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome.Blood advances · 2022Article
- Impact of fluid overload and infection on respiratory adverse event development during induction therapy for childhood acute myeloid leukemia.Pediatric blood & cancer · 2019Article
- Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children.Journal of the Pediatric Infectious Diseases Society · 2017Review
- Article
- Imaging of acute and subacute toxicities of cancer therapy in children.Pediatric radiology · 2016Review
- Concise review: next-generation cell therapies to prevent infections in neutropenic patients.Stem cells translational medicine · 2014Review
- Children's Oncology Group's 2013 blueprint for research: cancer control and supportive care.Pediatric blood & cancer · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To determine among children with acute myeloid leukemia, whether the proportions of life-threatening or fatal infections differed according to the intensity of induction or type of intensification treatment. Participants were children enrolled to the Children's Cancer Group (CCG) 2891 with de novo acute myeloid leukemia. In phase 1 (induction) patients were randomized to 4 cycles of chemotherapy either administered as intensive or standard timing. In phase 2 (intensification), those achieving remission were allocated to allogeneic stem cell transplantation (SCT) if a suitable family donor was available while the remainder were randomized to autologous SCT or chemotherapy. Each infection was classified prospectively as nonlife-threatening, life-threatening, or fatal. The proportion of all infections that were considered life-threatening or fatal was higher with intensive timing compared with standard timing induction (60.3% vs. 37.3%, P<0.0001). Infections caused by Gram-positive and Gram-negative bacteria and fungi were significantly more likely to be severe during intensive compared with standard timing induction. Most molds were life-threatening or fatal. Chemotherapy intensification was not associated with less severe infections compared with SCT. Intensive timing was associated with more severe infections compared with standard timing induction. Prophylactic strategies are likely more important with intensive induction regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.